{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:08:28Z","timestamp":1789474108456,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anti-CGRP monoclonal antibodies have shown notable effectiveness and tolerability in migraine patients; however, data on their use in elderly patients is still lacking, as clinical trials have implicit age restrictions and real-world evidence is scarce. In this study, we aimed to describe the safety and effectiveness of erenumab, galcanezumab and fremanezumab in migraine patients over 65\u00a0years old in real-life.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this observational real-life study, a retrospective analysis of prospectively collected data from 18 different headache units in Spain was performed. Migraine patients who started treatment with any anti-CGRP monoclonal antibody after the age of 65\u00a0years were included. Primary endpoints were reduction in monthly migraine days after 6\u00a0months of treatment and the presence of adverse effects. Secondary endpoints were reductions in headache and medication intake frequencies by months 3 and 6, response rates, changes in patient-reported outcomes and reasons for discontinuation. As a subanalysis, reduction in monthly migraine days and proportion of adverse effects were also compared among the three monoclonal antibodies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 162 patients were included, median age 68\u00a0years (range 65\u201387), 74.1% women. 42% had dyslipidaemia, 40.3% hypertension, 8% diabetes, and 6.2% previous cardiovascular ischaemic disease. The reduction in monthly migraine days at month 6 was 10.1\u2009\u00b1\u20097.3\u00a0days. A total of 25.3% of patients presented adverse effects, all of them mild, with only two cases of blood pressure increase. Headache and medication intake frequencies were significantly reduced, and patient-reported outcomes were improved. The proportions of responders were 68%, 57%, 33% and 9% for reductions in monthly migraine days\u2009\u2265\u200930%,\u2009\u2265\u200950%,\u2009\u2265\u200975% and 100%, respectively. A total of 72.8% of patients continued with the treatment after 6\u00a0months. The reduction in migraine days was similar for the different anti-CGRP treatments, but fewer adverse effects were detected with fremanezumab (7.7%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Anti-CGRP mAbs are safe and effective treatments in migraine patients over 65\u00a0years old in real-life clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s10194-023-01585-2","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T07:28:17Z","timestamp":1685690897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65\u00a0years: a real-life multicentre analysis of 162 patients"],"prefix":"10.1186","volume":"24","author":[{"given":"Albert","family":"Mu\u00f1oz-Vendrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Campoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Caronna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Alpuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Torres-Ferrus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candela","family":"Nieves Castellanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Campdelacreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cami\u00f1a Mu\u00f1iz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Jos\u00e9","family":"Molina Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ane","family":"M\u00ednguez-Olaondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ruibal Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Santos Lasaosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Pilar","family":"Navarro P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Moroll\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"L\u00f3pez Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Miguel","family":"Cano S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia Mar\u00eda","family":"Garc\u00eda-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9sica","family":"Garc\u00eda-Ull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rubio-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Gonzalez-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Quintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Echavarr\u00eda \u00cd\u00f1iguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sendoa","family":"Gil Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Victoria","family":"Castro-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Adell Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Garc\u00eda Alhama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Berrocal-Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Belv\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"D\u00edaz-Insa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Huerta-Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"1585_CR1","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0140-6736(19)32504-8","volume":"394","author":"A Charles","year":"2019","unstructured":"Charles A, Pozo-Rosich P (2019) Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 394:1765\u20131774. https:\/\/doi.org\/10.1016\/S0140-6736(19)32504-8","journal-title":"Lancet"},{"key":"1585_CR2","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, Goadsby PJ, Reuter U et al (2021) Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28:1716\u20131725. https:\/\/doi.org\/10.1111\/ene.14715","journal-title":"Eur J Neurol"},{"key":"1585_CR3","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40264-021-01119-2","volume":"44","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Ning X et al (2021) Long-term safety and tolerability of Fremanezumab for migraine preventive treatment in Japanese outpatients: a multicenter, randomized, open-label study. Drug Saf 44:1355\u20131364. https:\/\/doi.org\/10.1007\/s40264-021-01119-2","journal-title":"Drug Saf"},{"key":"1585_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10072-020-04669-y","volume":"41","author":"F Vernieri","year":"2020","unstructured":"Vernieri F, Altamura C, Aurilia C et al (2020) Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study). Neurol Sci 41:487\u2013488. https:\/\/doi.org\/10.1007\/s10072-020-04669-y","journal-title":"Neurol Sci"},{"key":"1585_CR5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME et al (2018) Effect of Fremanezumab compared with placebo for prevention of episodic migraine. JAMA 319:1999. https:\/\/doi.org\/10.1001\/jama.2018.4853","journal-title":"JAMA"},{"key":"1585_CR6","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377:2113\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa1709038","journal-title":"N Engl J Med"},{"key":"1585_CR7","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394:1030\u20131040. https:\/\/doi.org\/10.1016\/S0140-6736(19)31946-4","journal-title":"Lancet"},{"key":"1585_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R et al (2020) Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40:241\u2013254. https:\/\/doi.org\/10.1177\/0333102420905132","journal-title":"Cephalalgia"},{"key":"1585_CR9","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/ane.13603","volume":"145","author":"V Martin","year":"2022","unstructured":"Martin V, Tassorelli C, Ettrup A et al (2022) Eptinezumab for migraine prevention in patients 50 years or older. Acta Neurol Scand 145:698\u2013705. https:\/\/doi.org\/10.1111\/ane.13603","journal-title":"Acta Neurol Scand"},{"key":"1585_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s10194-021-01351-2","volume":"22","author":"SJ Nahas","year":"2021","unstructured":"Nahas SJ, Naegel S, Cohen JM et al (2021) Efficacy and safety of fremanezumab in clinical trial participants aged \u226560 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies. J Headache Pain 22:141. https:\/\/doi.org\/10.1186\/s10194-021-01351-2","journal-title":"J Headache Pain"},{"key":"1585_CR11","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim B-K, L\u00e1inez MJA et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19:814\u2013825. https:\/\/doi.org\/10.1016\/S1474-4422(20)30279-9","journal-title":"Lancet Neurol"},{"key":"1585_CR12","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.1007\/s10072-022-06190-w","volume":"43","author":"I Cetta","year":"2022","unstructured":"Cetta I, Messina R, Zanandrea L et al (2022) Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study. Neurol Sci 43:5769\u20135771. https:\/\/doi.org\/10.1007\/s10072-022-06190-w","journal-title":"Neurol Sci"},{"key":"1585_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"key":"1585_CR14","unstructured":"Ministerio de Sanidad, Consumo y Bienestar Social, Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terap\u00e9utico de erenumab (Aimovig\u00ae) en la profilaxis de migra\u00f1a. IPT 62\/2019 V1, (15 de noviembre de 2019). Informe de Posicionamiento Terap\u00e9utico de galcanezumab (Emgality\u00ae) en la profilaxis de migra\u00f1a. IPT 63\/2019 V1, (15 de noviembre de 2019). Informe de Posicionamiento Terap\u00e9utico de fremanezumab (Ajovy\u00ae) en la profilaxis de migra\u00f1a. IPT, 11\/2020. V1. [1 Oct 2022]."},{"key":"1585_CR15","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1111\/ene.15075","volume":"28","author":"LS de Vries","year":"2021","unstructured":"de Vries LS, Verhagen IE, van den Hoek TC et al (2021) Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study. Eur J Neurol 28:4194\u20134203. https:\/\/doi.org\/10.1111\/ene.15075","journal-title":"Eur J Neurol"},{"key":"1585_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Altamura C, Brunelli N et al (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22:35. https:\/\/doi.org\/10.1186\/s10194-021-01247-1","journal-title":"J Headache Pain"},{"key":"1585_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s10194-022-01396-x","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C et al (2022) Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain 23:46. https:\/\/doi.org\/10.1186\/s10194-022-01396-x","journal-title":"J Headache Pain"},{"key":"1585_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-021-01328-1","volume":"22","author":"E Caronna","year":"2021","unstructured":"Caronna E, Gallardo VJ, Alpuente A et al (2021) Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months. J Headache Pain 22:120. https:\/\/doi.org\/10.1186\/s10194-021-01328-1","journal-title":"J Headache Pain"},{"key":"1585_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/WCO.0000000000001061","volume":"35","author":"I-A Koumprentziotis","year":"2022","unstructured":"Koumprentziotis I-A, Mitsikostas DD (2022) Therapies targeting CGRP signaling for medication overuse headache. Curr Opin Neurol 35:353\u2013359. https:\/\/doi.org\/10.1097\/WCO.0000000000001061","journal-title":"Curr Opin Neurol"},{"key":"1585_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s10194-021-01338-z","volume":"22","author":"EC McKinley","year":"2021","unstructured":"McKinley EC, Lay CL, Rosenson RS et al (2021) Risk for ischemic stroke and coronary heart disease associated with migraine and migraine medication among older adults. J Headache Pain 22:124. https:\/\/doi.org\/10.1186\/s10194-021-01338-z","journal-title":"J Headache Pain"},{"key":"1585_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40266-020-00776-9","volume":"37","author":"PP Soni","year":"2020","unstructured":"Soni PP, Lee M, Shadbehr N, Ahmed ZA (2020) Recent advances in the management of migraine in older patients. Drugs Aging 37:463\u2013468. https:\/\/doi.org\/10.1007\/s40266-020-00776-9","journal-title":"Drugs Aging"},{"key":"1585_CR22","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s13311-022-01230-x","volume":"19","author":"F Cohen","year":"2022","unstructured":"Cohen F, Yuan H, DePoy EMG, Silberstein SD (2022) The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine. Neurotherapeutics 19:922\u2013930. https:\/\/doi.org\/10.1007\/s13311-022-01230-x","journal-title":"Neurotherapeutics"},{"key":"1585_CR23","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1111\/head.13956","volume":"60","author":"A Alex","year":"2020","unstructured":"Alex A, Vaughn C, Rayhill M (2020) Safety and tolerability of 3 CGRP monoclonal antibodies in practice: a retrospective cohort study. Headache J Head Face Pain. 60:2454\u20132462. https:\/\/doi.org\/10.1111\/head.13956","journal-title":"Headache J Head Face Pain."},{"key":"1585_CR24","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1007\/s13311-021-01128-0","volume":"18","author":"C-P Yang","year":"2021","unstructured":"Yang C-P, Zeng B-Y, Chang C-M et al (2021) Comparative effectiveness and tolerability of the pharmacology of monoclonal antibodies targeting the calcitonin gene-related peptide and its receptor for the prevention of chronic migraine: a network meta-analysis of randomized controlled trials. Neurotherapeutics 18:2639\u20132650. https:\/\/doi.org\/10.1007\/s13311-021-01128-0","journal-title":"Neurotherapeutics"},{"key":"1585_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12883-020-01633-3","volume":"20","author":"H Deng","year":"2020","unstructured":"Deng H, Li G, Nie H et al (2020) Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine \u2013 an updated systematic review and meta-analysis. BMC Neurol 20:57. https:\/\/doi.org\/10.1186\/s12883-020-01633-3","journal-title":"BMC Neurol"},{"key":"1585_CR26","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1080\/01616412.2021.1940672","volume":"43","author":"M Shi","year":"2021","unstructured":"Shi M, Guo J, Li Z et al (2021) Network meta-analysis on efficacy and safety of different anti-CGRP monoclonal antibody regimens for prophylaxis and treatment of episodic migraine. Neurol Res 43:932\u2013949. https:\/\/doi.org\/10.1080\/01616412.2021.1940672","journal-title":"Neurol Res"},{"key":"1585_CR27","doi-asserted-by":"publisher","unstructured":"Messina R, Huessler E-M, Puledda F, et al (2023) Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis. Cephalalgia. 43(3). https:\/\/doi.org\/10.1177\/03331024231152169","DOI":"10.1177\/03331024231152169"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01585-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01585-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01585-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T07:28:29Z","timestamp":1685690909000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01585-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1585"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01585-2","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]},"assertion":[{"value":"9 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AMV, SC, JC and JP have received honoraria from Teva, Lilly, Roche, UCB, Bial, Chiesi, Allergan, Esai, Zambon, Kern Pharma, Pfizer, Biogen Idec, Novartis, TEVA, Merck, Janssen, Neuraxpharm, Genzyme, Sanofi, Bayer, Almirall and\/or Celgene.EC has received honoraria from Novartis, Chiesi, Lundbeck, Medscape. He is junior editor for Cephalalgia.Marta Torres-Ferrus has received honoraria as a consultant or speaker for Allergan-Abbvie, Almirall, Chiesi, Eli Lilly, Novartis, and Teva.Alicia Alpuente has received honoraria as speaker from Abbvie and for education from Novartis and Eli Lilly.CN has received honoraria from Lilly, Novartis, Teva and Chiesi.JCM has received honoraria from Lilly, Novartis, Teva, Abbvie-Allergan, Lundbeck, Chiesi, Bial, Neuraxpharm, Schwabe. FJMM has received honoraria from Lilly, Novartis, Teva, Abbvie-Allergan y Chiesi.AMO has received honoraria from Lilly, Novartis, Allergan-Abbvie, Bial, Eisai, Gr\u00fcnenthal, Almirall or Neuraxpharm.SSL has received honoraria from Allergan, Amgen, Chiesi, Eisai, Exeltis, Novartis, and Teva.NM has received honoraria from Teva, Novartis, Lilly and Abbvie.LMCS and SMGS have received honoraria from Lilly and Teva.AGM has received education funding from Lilly, Novartis, Roche, TEVA, Abbvie-Allergan, & Daichi and speaker honoraria from TEVA.NBI has received honoraria from Zambon, Actelion, Lilly and Teva.RB has received honoraria from Abbvie, Neuraxpharma, Abbott, Teva, Novartis, Pfizer, Lilly, Almirall, Noema, Exeltis, Ergon, Neurodiem, Menarini, Biogen, Lundbeck and Medtronik.SD has received honoraria from Abbvie, Ipsen, Lilly, Lundbeck, Novartis and Teva.P.P.R. has received honoraria as a consultant and speaker, in the last three years, for: AbbVie, Amgen, Biohaven, Chiesi, Eli Lilly, Lundbeck, Medscape, Novartis, Pfizer and Teva. Her research group has received research grants from AbbVie, Novartis and Teva; and, has received funding for clinical trials from Alder, AbbVie, Amgen, Biohaven, Electrocore, Eli Lilly, Lundbeck, Novartis and Teva. She is the Honorary Secretary of the International Headache Society. She is in the editorial board of Revista de Neurologia, associate editor for Cephalalgia, Headache, Neurologia, Frontiers of Neurology. She is a member of the Clinical Trials Guidelines Committee and Scientific Committee of the International Headache Society. She has edited the Guidelines for the Diagnosis and Treatment of Headache of the Spanish Neurological Society. She is the founder of . Pozo-Rosich P does not own stocks from any pharmaceutical company.MH-V has received honoraria for participating on advisory boards and for collaborations as consultant, scientific communications, speaker, research support as well as funding for travel and congress-attending expenses for Abbie-Allergan, Novartis, Lilly, Almirall, Chiesi, Esai, Exeltis, Kern Pharma, Menarini, TEVA and Zambon. His research group has received research grants from Abbie-Allergan; and has received funding for clinical trials from Lilly, Novartis, TEVA.MO, MRS, MPNP, ALB, JGU, LRF, SQ, AEI, SGL, MVCS, VAO and JGA have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}